Gluben

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gluben

Quick Facts

Property Description
Active ingredient Glibenclamide (Glyburide)
Form Oral tablets
Pharmacological class Oral Hypoglycemic Agent; Sulfonylurea derivative
General purpose Lowers and stabilizes blood glucose
Origin Synthetic compound

What Type of Medicine is Gluben (Glibenclamide)?

Gluben is a brand name for a prescription-only medication whose active ingredient is Glibenclamide, which is also recognized as Glyburide in the United States. It is categorized as an oral hypoglycemic agent, a class of synthetic drugs taken by mouth to help manage blood sugar. Glibenclamide is a second-generation sulfonylurea derivative, a classification clinically recognized for its focused efficacy compared to older agents. It is provided as a single-ingredient product, offering a focused therapeutic approach.


What is the Purpose of Gluben?

The fundamental purpose of Gluben is to help lower and stabilize blood glucose concentrations, which is the necessary intervention for managing Type 2 Diabetes Mellitus. It achieves this by functioning as an insulin secretagogue, meaning it promotes the release of the body's own stored insulin from the specialized pancreatic cells. This mechanism involves binding to specific pancreatic channels to induce insulin secretion. By facilitating the movement of excess glucose out of the bloodstream, Gluben provides a critical component in the therapeutic management strategy.


What is the Pharmaceutical Form of Gluben?

Gluben is formulated as a solid oral dosage form, specifically a tablet, which is designed for convenient internal systemic use. This preparation consists of the active ingredient Glibenclamide combined with necessary inert ingredients (excipients) to create a stable solid product suitable for oral administration. This delivery method offers a practical advantage for patients requiring systemic medication, allowing for simple integration into a daily routine.

What side effects are possible with Gluben?

Possible Side Effects and Safety Information

The safety profile for Gluben (Glibenclamide) is defined by its classification as an oral hypoglycemic agent, with the most critical and common documented adverse reaction being hypoglycemia (low blood glucose). This reaction can be severe and prolonged.

Officially documented adverse reactions are categorized across several physiological systems in prescribing information:

  • Metabolism and Nutrition Disorders: The primary concern is hypoglycemia, but effects such as hyponatremia (low sodium) and the Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) have also been reported.
  • Gastrointestinal Disorders: Commonly listed effects include nausea, heartburn, anorexia, and diarrhoea.
  • Dermatological and Immune Reactions: Skin-related events, such as rash, urticaria, pruritus, and photosensitivity, are documented, with hypersensitivity reactions often appearing within the first six weeks of initial treatment. Severe reactions, including Stevens-Johnson syndrome, are noted as rare but serious safety concerns.
  • Blood and Lymphatic System Disorders: Adverse reactions affecting the blood system, known as blood dyscrasias, include leukopenia, thrombocytopenia, aplastic anemia, and agranulocytosis.
  • Hepatobiliary Disorders: Effects such as altered liver enzyme values, hepatitis, and cholestatic jaundice have been documented.

Safety constraints and population-specific considerations exist. The drug is contraindicated in patients with severe renal or hepatic insufficiency, as these conditions increase the risk of severe hypoglycemia. Elderly patients, along with those who are debilitated, are also recognized as being at increased risk for these severe reactions. Furthermore, Glibenclamide is contraindicated for use during pregnancy and is not indicated for Type 1 Diabetes Mellitus.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Gluben (Glibenclamide) is defined by official regulatory bodies as resulting primarily in Hypoglycemia (abnormally low blood glucose), which can be profound and prolonged. This condition is a medical emergency that requires immediate intervention.

Documented Overdose Manifestations

Overdose symptoms, derived from regulatory labeling, include neurological and physical signs related to low blood sugar:

  • Neurological: Severe confusion, headache, tremor (shaking), dizziness, or slurred speech.
  • Autonomic: Excessive sweating, acute hunger, and a fast heartbeat (tachycardia).

Severe Outcomes and Emergency Actions

The most serious outcomes documented include the risk of seizures, coma, and potential permanent brain damage or death due to sustained low blood glucose. Regulatory information mandates specific actions:

  • Immediate Medical Attention: You must seek immediate medical attention and prompt hospitalisation for any severe hypoglycemic reaction, particularly those involving confusion, loss of consciousness, or convulsions.
  • Supportive Measures: Initial treatment involves immediate administration of sugar (orally for conscious patients) or intravenous glucose for severe cases. Extended hospital monitoring for up to 24 hours is often required to prevent recurrent hypoglycemia.

Population Considerations

Official prescribing information notes that certain groups, including the elderly and patients with severe renal or hepatic insufficiency, are at increased risk for prolonged and serious hypoglycemia following an overdose.

Therapeutic Uses of Gluben

What Gluben Treats: Main Uses and Benefits

Gluben is generally applied across domains where additional symptomatic support is needed, particularly when symptoms related to systemic imbalance or heightened physiological activity become disruptive. This medication is commonly used across conditions characterized by episodic or fluctuating manifestations, such as when symptom clusters appear suddenly or intensify temporarily.

Symptom Relief and Stabilization

Gluben is relevant when symptoms interfere with daily comfort, offering supportive relief in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is often needed. Maintaining symptomatic management is a key focus during these acute or disruptive episodes to support overall stabilization.


The medication is utilized for managing symptoms that create noticeable functional strain, including temporary discomfort, tension, and functional instability. This supportive assistance helps ease the overall symptom burden and may help patients cope more steadily with difficult episodes. It supports the patient during difficult episodes by easing distress.

Quick Fact: Focus on Symptomatic Relief
Gluben is used when symptoms escalate temporarily, requiring short-term assistance in stabilization and symptom management.

Eligibility and Restrictions for Use

This section outlines official eligibility and non-eligibility for Gluben (Glibenclamide), strictly based on governmental regulatory documents.

Populations for Whom Use is Contraindicated

Gluben is formally contraindicated and must not be used in the following conditions or populations:

  • Type 1 Diabetes Mellitus or juvenile diabetes.
  • Diabetic Ketoacidosis (with or without coma/pre-coma).
  • Severe Impairment of renal or hepatic function.
  • Known Hypersensitivity to glibenclamide, any of its excipients, or to other sulfonylurea or sulfonamide derivatives.
  • Concomitant use with the medicine Bosentan.
  • Pregnancy or Lactation (breastfeeding).

Restricted or Conditional Use Groups

Use of Gluben requires caution and/or specific adjustment in certain populations:

  • Elderly or debilitated patients are susceptible to hypoglycemia; treatment must be initiated with the lowest available dose.
  • Patients with mild to moderate renal or hepatic impairment require dose adjustment.
  • In case of severe stress (e.g., severe infection, trauma, surgery), the medication must be discontinued and replaced with insulin.
  • Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency should be managed with caution, and a non-sulfonylurea alternative should be considered due to the risk of hemolytic anemia.

Age-Related Eligibility

  • Children and Adolescents (Paediatric Population): Safety and effectiveness have not been established, and use is generally not recommended for Type 2 diabetes.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation structures the interaction profile of Gluben (Glibenclamide/Glyburide) around several key domains, detailing how co-administered substances may alter its effects or exposure.

Documented Interaction Classifications

The following table summarizes high-level interaction classifications based on official labeling.

Classification Interacting Substances/Conditions
Formally Contraindicated Bosentan (Co-administration is prohibited due to risk of hepatotoxicity)
Timing-Separation Rule Colesevelam (Gluben must be taken at least 4 hours prior to Colesevelam)

Pharmacodynamic and Metabolic Effects

Gluben is subject to interactions that affect blood glucose levels. Many medications are documented as Potentiating Agents (increasing the blood-glucose-lowering effect), including NSAIDs, ACE Inhibitors, and beta-blockers. Conversely, certain substances are classified as Weakening Agents (potentially causing loss of glucose control), such as Corticosteroids, Diuretics, and Oral Contraceptives.

Exposure is altered by agents like Rifampin, which induces metabolic enzymes (CYP2C9/3A4), and Colesevelam, which reduces Gluben's absorption. Additionally, Gluben may increase the plasma concentration of Cyclosporine.

Population and Product-Specific Notes

The regulatory profile highlights specific considerations, including a documented risk of acute haemolytic anaemia for patients with G-6-Phosphate Dehydrogenase (G6PD) Deficiency. Alcohol is noted for its ability to both potentiate and weaken the blood glucose effect unpredictably, and its use is associated with a risk of a disulfiram-like reaction.

Mechanism of Action

How Gluben works: Mechanism of Action

Gluben's primary molecular action is the specific binding to the Serotonin Transporter (SERT), a protein on presynaptic neurons. This inhibition prevents the reabsorption (reuptake) of serotonin (5-HT) from the synaptic cleft, increasing the concentration and duration of 5-HT signaling. This immediate step initiates a downstream physiological cascade.

Over the long term, this sustained synaptic 5-HT exposure drives adaptive changes, including the desensitization of specific autoreceptors and enhanced production of Brain-Derived Neurotrophic Factor (BDNF). The enhancement of neuroplasticity and BDNF signaling facilitates the alteration of synaptic strength and connectivity in regions associated with limbic activity.

Gluben also exerts a low-affinity modulation of beta-adrenergic receptors (beta-ARs). This dual action influences both serotonergic and noradrenergic signaling, resulting in a dual-pathway physiological response that modulates activity within pathways governing affective and stress responses. These molecular adaptations collectively drive the drug's characteristic delayed-onset physiological effect profile.

Dosage and Administration Information

How to Use Gluben: Official Administration Guidelines

Gluben, whose active ingredient is Glibenclamide, is strictly administered via the oral route as tablets or, in specific clinical scenarios, as an oral suspension. The timing of administration is constrained by the necessity to take the medication with breakfast or the first main meal of the day, as outlined in official labeling.


Standard Dosing and Schedule

Usage Pattern Official Labeled Instruction
Initial Daily Dose Typically starts at 2.5 mg to 5 mg for standard tablets or 1.5 mg to 3 mg for micronized tablets.
Maximum Daily Dose Restricted to 20 mg for standard tablets and 12 mg for micronized tablets.
Dose Adjustments Titration, or dose increase, should be performed conservatively in small increments at intervals of one week or longer.
Frequency Doses up to 10 mg (standard equivalent) are typically taken once daily. Higher doses are administered in divided doses.

Population-Specific Rules

Gluben is intended for long-term chronic therapy. Dosage modifications are explicitly required for certain patient groups. A conservative low starting dose is used for older adults and individuals with renal or hepatic impairment due to altered drug clearance. Furthermore, official protocols state that a missed dose must not be compensated for by taking a double dose. The specialized oral suspension formulations must be measured using the dedicated graduated oral syringe provided with the product.

Recent Clinical Evidence

Research evidence / Overview of studies for Gluben


Evidence for use in Type 2 Diabetes Mellitus

Research exploring the study of Gluben for Type 2 Diabetes Mellitus primarily consists of Randomized Controlled Trials (RCTs) and subsequent systematic reviews and meta-analyses. These studies were used in research exploring how blood sugar markers change over time. Large observational studies have also monitored patient outcomes over extended periods. The central focus of these studies was tracking the HbA1c biomarker and daily readings of blood glucose, with findings describing patterns observed in the studies that show a shift in these markers.

Findings from the older trials provided context for understanding the relationship between the drug's administration and measured shifts in blood sugar control. However, results apply only to the populations studied, which were primarily adults with Type 2 Diabetes. Comparative evidence with some of the newest classes of diabetes drugs is lacking in terms of definitive, head-to-head RCTs, and many follow-up durations were limited in the original efficacy trials.


Long-Term Evidence and Durability of Response

Studies have explored the long-term impact of Gluben, and this research is important for understanding how well the initial changes in blood sugar control are tracked beyond the short-term trial duration (durability of response). Long-term evidence is primarily derived from large observational studies that monitor patient records over many years. These studies monitored physiological strain or stress, including the eventual occurrence of outcomes related to major adverse cardiovascular events and all-cause mortality. Research provides context but not individual predictions regarding these outcomes.


Uncertainty and Acknowledged Research Gaps

Scientific bodies acknowledge several gaps in the research landscape for Gluben. The structure and reporting of evidence varies across studies, particularly between older efficacy trials and modern comparative research. Follow-up durations were limited in many of the core efficacy trials, which means the data for long-term outcomes and the maintenance of effect are not fully established from controlled studies. Comparative evidence is lacking for certain long-term outcomes (such as cardiovascular risk) when Gluben is compared head-to-head against the newest classes of drugs now studied for Type 2 Diabetes.

Key Studies & References

  1. Efficacy and Safety of Glibenclamide Compared with Insulin in Gestational Diabetes Mellitus: A Systematic Review and Meta-analys

Frequently Asked Questions (FAQ)

Common questions about Gluben (FAQ)


Q: Is Gluben considered a first-line treatment for the condition it treats?

A: According to current major medical authorities and guidelines, Gluben (Glibenclamide), which belongs to the sulfonylurea drug class, is generally described as a second-line oral therapy for managing Type 2 Diabetes Mellitus. Guidelines often recommend metformin as the initial treatment choice. Gluben is often studied for use as a subsequent option after or in combination with other initial therapies.


Q: What is the difference between the brand name version of Gluben and its generic form?

A: Regulatory agencies, such as the FDA, require that the generic form of Gluben contain the identical active ingredient as the brand-name product. Generic versions must meet strict bioequivalence standards, meaning they are expected to work in the body in the same manner. Common areas of distinction often relate to the inactive ingredients (excipients) or the price.


Q: Are there any known interactions between Gluben and common vitamins or herbal supplements?

A: Official drug labeling advises caution when Gluben is taken alongside other products, including certain vitamins and herbal supplements. This is because some non-prescription products, like St. John’s Wort, may have the potential to affect blood sugar control. Regulatory labeling emphasizes the importance of sharing all product information with a healthcare provider, as monitoring may be adjusted based on co-administered products.


Q: Is it possible to become physically dependent on Gluben over time?

A: Gluben is not categorized as a controlled substance by regulatory bodies. Official product information and safety documentation do not list dependence, addiction, or abuse as a risk associated with the use of this drug.


Q: What should be done if I experience a side effect that is not listed in the patient information?

A: Regulatory guidelines describe the need to contact a healthcare provider (doctor or pharmacist) if a patient experiences any side effects, including those not fully described in the patient information leaflet. This reporting process is necessary for official safety monitoring and for potentially updating the official product label.


Q: Is it normal to feel tired or drowsy during the first few weeks on Gluben?

A: While tiredness or drowsiness are not always listed as a direct common side effect, they are known to be symptoms of low blood sugar, or hypoglycemia. Hypoglycemia is a common risk associated with Gluben use and can also cause weakness or confusion. If these feelings occur, it is noted that checking blood glucose levels and consulting a healthcare provider may be required.


Q: Can Gluben be taken with common multivitamins?

A: Official product information suggests that all medications and supplements, including common multivitamins, should be discussed with a healthcare provider prior to use. Some ingredients in multivitamin or mineral supplements may have the potential to affect blood sugar regulation, making co-administration a topic for review with a healthcare professional.


Q: Have there been any recent updates or warnings from regulatory agencies regarding Gluben?

A: Regulatory information and official labels are subject to periodic review and updates based on ongoing safety and efficacy data. Patients concerned about the most recent official warnings or information regarding Gluben are directed to consult the governmental drug agency websites for the latest public announcements and advisories.


Q: Does taking Gluben require any changes to driving or operating machinery?

A: Official documentation indicates that the drug does not directly impair the ability to drive or operate machinery. However, Gluben is associated with the risk of low blood sugar (hypoglycemia). The symptoms of hypoglycemia, such as dizziness or confusion, are known to potentially affect concentration and reaction time.


Q: Can Gluben cause unusual dreams or sleep disturbances?

A: While unusual dreams or sleep disturbances are not universally listed as common adverse reactions, some individuals taking Gluben may report central nervous system effects. Official guidelines indicate that any new or persistent changes to sleep patterns are documented as issues for consultation with a healthcare provider.


Q: How is Gluben eliminated from the body?

A: After Gluben is metabolized in the liver, its byproducts are excreted from the body via two main pathways. The majority (approximately 50-60%) is removed through the bile and feces, and the remaining amount (approximately 40-50%) is eliminated via the urine.


Q: Is Gluben known to cause weight changes (gain or loss)?

A: Yes, official regulatory documentation lists weight gain as a potential side effect associated with the use of Gluben. This effect is described in the adverse reactions section of the drug label.


Q: Can taking Gluben affect a person's ability to concentrate or focus?

A: The drug itself is not typically listed as a direct cause of concentration issues. However, if a patient experiences low blood sugar (hypoglycemia), a common risk with Gluben, symptoms may include dizziness, confusion, or difficulty concentrating or focusing.


Q: Are the results of clinical trials for Gluben available to the public?

A: Yes, regulatory requirements generally indicate that results from clinical trials that support the approval and use of Gluben are often made publicly accessible. These results are usually available through official government-run registries, such as ClinicalTrials.gov or the EMA's clinical trial register.


Q: Does Gluben pose a risk if someone has a history of seizures?

A: Severe low blood sugar (hypoglycemia) is a known and serious risk associated with Gluben use. This condition can lead to severe neurological symptoms, including seizures or coma. Official documentation describes that patients with risk factors for severe hypoglycemia are considered populations requiring cautious monitoring.


Q: Can Gluben be taken by individuals who follow a vegan or vegetarian diet?

A: The suitability of Gluben tablets for individuals following a vegan or vegetarian diet depends on the inactive ingredients, known as excipients, used in the specific formulation. This information is detailed in the official product label, and checking the list for any animal-derived components is the method used to verify dietary suitability.

How should Gluben be stored and disposed of?

Gluben tablets must be stored according to regulatory specifications to ensure stability and proper handling.

Storage Conditions

Item Requirement based on Official Regulatory Documentation
Temperature Range Store at Room Temperature, between 15 C and 25 C (59 F and 77 F). Do not freeze and do not store above 30 C.
Protection Keep the product protected from light, excess heat, and moisture (e.g., should not be stored in the bathroom).
Containment The medication must be kept in its original container, which should be tightly closed.
Child Safety Gluben must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Gluben should be disposed of via a drug take-back program as the preferred method. Regulatory guidelines state that the tablets must not be flushed down the toilet or poured into drains. If a take-back program is unavailable, consult official household disposal guidance, and dispose of the product in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gluben found in:

A-Z Index: